Home / Publication / Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

論文

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

Author(s): Tiago Nava, Nastya Kassir, Mohamed Aziz, Rezgui Chakradhara Rao Satyanarayana Uppugunduri, Patricia Huezo-Diaz Curtis, Michel Duval, Yves Théore, Liane E. Daudt, Catherine Litalien, Marc Ansari, Maja Krajinovic, Henrique Bittencourt

Year: 2018年2月22日

How Model-informed drug development rescue projects from a risky situation

事例紹介

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

論文

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

ウェビナー

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

ウェビナー

Powered by Translations.com GlobalLink Web Software

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

How Model-informed drug development rescue projects from a risky situation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

How Model-informed drug development rescue projects from a risky situation​

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation